Efficient inactivation of the p53 pathway by BCR–ABL1 and its downstream targets may explain why genetic mutations or deletions of p53 are rare up-front in Ph+ ALL (199, 200). This evidence concerns the gene TP53 and acute lymphoblastic leukemia.